menu
    • menu

    Company profile for Paradigm Biopharmaceuticals

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Paradigm Biopharmaceuticals Ltd (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for the treatment of conditions that begin with and are sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. Our lead clinical indications include treating bone marrow edema (BME), an increasingly recognised pathological ...
    Paradigm Biopharmaceuticals Ltd (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for the treatment of conditions that begin with and are sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. Our lead clinical indications include treating bone marrow edema (BME), an increasingly recognised pathological change in bone and a significant contributor to pain and symptoms in Osteoarthritis and acute joint injury; and the treatment of joint function, mobility and pain in patients with mucopolysaccharidoses (MPS).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Paradigm BiopharmaceuticalsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Care of Hollingsworth, L2 517 Flinders Lane, Melbourne, Victoria 3000, AU
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://paradigmbiopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/paradigm-biopharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Paradigm says PhII trial in osteoarthritis shows signs of disease modification
    Paradigm says PhII trial in osteoarthritis shows signs of disease modification

    11 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/11/2644128/0/en/Australia-s-Paradigm-Biopharmaceuticals-says-phase-2-trial-in-osteoarthritis-shows-signs-of-disease-modification-at-6-month-follow-up.html

    GLOBENEWSWIRE
    11 Apr 2023
    Share Share
    Paradigm debuts with $203M series A funding
    Paradigm debuts with $203M series A funding

    31 Jan 2023

    // Joseph Keenan FIERCE BIOTECH

    https://www.fiercebiotech.com/cro/paradigm-debuts-203m-series-funding-focused-trial-platform-patient-diversity

    Joseph Keenan FIERCE BIOTECH
    31 Jan 2023
    Share Share
    Paradigm Achieves Primary Endpoint in PARA_OA_008 PII Trial
    Paradigm Achieves Primary Endpoint in PARA_OA_008 PII Trial

    04 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/paradigm-achieves-primary-endpoint-in-paraoa008-synovial-fluid-biomarker-phase-2-clinical-trial-301640478.html

    PRNEWSWIRE
    04 Oct 2022
    Share Share
    Paradigm Partners with NFL Alumni Health on Osteoarthritis Program
    Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

    14 Jul 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/paradigm-partners-with-nfl-alumni-health-on-osteoarthritis-program-301587025.html

    PRNEWSWIRE
    14 Jul 2022
    Share Share
    Paradigm Bio begins UK-based screening for PIII study assessing Zilosul
    Paradigm Bio begins UK-based screening for PIII study assessing Zilosul

    06 Jul 2022

    // Phoebe Shields PROACTIVEINVESTORS

    https://www.proactiveinvestors.com.au/companies/news/986695/paradigm-biopharmaceuticals-begins-uk-based-screening-for-phase-3-study-assessing-zilosul-on-knee-oa-986695.html

    Phoebe Shields PROACTIVEINVESTORS
    06 Jul 2022
    Share Share
    Paradigm Biopharmaceuticals Appoints Marco Polizzi As Chief Executive Officer
    Paradigm Biopharmaceuticals Appoints Marco Polizzi As Chief Executive Officer

    27 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/paradigm-biopharmaceuticals-ltd-appoints-marco-polizzi-as-chief-executive-officer-301576040.html

    PRNEWSWIRE
    27 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search